Theravance COPD drug on track for FDA decision by November

Revefenacin, a nebulized long-acting muscarinic antagonist, has had a checkered past.

The FDA accepted Theravance Biopharma and Mylan’s nebulized chronic obstructive pulmonary disease drug for review, with a PDUFA date of Nov. 13. If cleared, revefenacin would be the first once-daily, nebulized bronchodilator for COPD.

Revefenacin, a nebulized long-acting muscarinic antagonist (LAMA), has had a checkered past—GlaxoSmithKline acquired the rights to revefenacin in 2004 but ditched the candidate after discovering its formulation was incompatible with its proprietary inhaler.

Without missing a beat, Theravance repositioned the drug as a nebulized product and the company now considers this a distinguishing feature.


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

RELATED: AstraZeneca’s triple-hit COPD inhaler meets goals in phase 3, setting up scrap with GlaxoSmithKline

"Today, patients with moderate to severe COPD do not have access to a nebulized LAMA as a treatment option yet. We believe revefenacin, when approved, represents an important advancement in respiratory care by offering a convenient once-daily option for patients and further strengthens Mylan's robust and growing respiratory portfolio," said Mylan President Rajiv Malik, in a statement.

“With positive results in our Phase 3 program, we believe that revefenacin is well positioned to fill this important need," said Rick Winningham, Theravance CEO. "I commend the team at Theravance Biopharma and Mylan for producing a high-quality submission, and we look forward to working with the FDA in its review of our application."

In July, the companies reported 12-month safety data from two phase 3 trials that showed revefenacin has a similar safety profile to Boehringer Ingelheim’s Spiriva; the data followed positive efficacy data from a pair of shorter phase 3 studies.

While Theravance and Mylan pitted their drug against Spiriva, Verona Pharma took a complementary approach—in September, the U.K.-based company unveiled phase 2a data that showed combining its RPL554 with Spiriva improved lung function in patients with COPD.

Suggested Articles

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.

The FDA rejected the New Drug Application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.